These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 10444280)

  • 21. Occurrence of inhibitors in previously untreated or minimally treated patients with haemophilia A after exposure to a plasma-derived solvent-detergent factor VIII concentrate.
    Gringeri A; Monzini M; Tagariello G; Scaraggi FA; Mannucci PM;
    Haemophilia; 2006 Mar; 12(2):128-32. PubMed ID: 16476086
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The immunogenicity of ReFacto AF (moroctocog alfa AF-CC) in previously untreated patients with haemophilia A in the United Kingdom.
    Mathias MC; Collins PW; Palmer BP; Chalmers E; Alamelu J; Richards M; Will A; Hay CRM;
    Haemophilia; 2018 Nov; 24(6):896-901. PubMed ID: 30004617
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Von Willebrand factor-containing factor VIII concentrates and inhibitors in haemophilia A. A critical literature review.
    Franchini M; Lippi G
    Thromb Haemost; 2010 Nov; 104(5):931-40. PubMed ID: 20838738
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel investigations on the protective role of the FVIII/VWF complex in inhibitor development.
    Mannucci PM; Shi Q; Bonanad S; Klamroth R
    Haemophilia; 2014 Sep; 20 Suppl 6():2-16. PubMed ID: 24975700
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A study of prospective surveillance for inhibitors among persons with haemophilia in the United States.
    Soucie JM; Miller CH; Kelly FM; Payne AB; Creary M; Bockenstedt PL; Kempton CL; Manco-Johnson MJ; Neff AT;
    Haemophilia; 2014 Mar; 20(2):230-7. PubMed ID: 24261612
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibitor development in haemophilia according to concentrate. Four-year results from the European HAemophilia Safety Surveillance (EUHASS) project.
    Fischer K; Lassila R; Peyvandi F; Calizzani G; Gatt A; Lambert T; Windyga J; Iorio A; Gilman E; Makris M;
    Thromb Haemost; 2015 May; 113(5):968-75. PubMed ID: 25567324
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recombinant factor VIII products and inhibitor development in previously untreated boys with severe hemophilia A.
    Calvez T; Chambost H; Claeyssens-Donadel S; d'Oiron R; Goulet V; Guillet B; Héritier V; Milien V; Rothschild C; Roussel-Robert V; Vinciguerra C; Goudemand J;
    Blood; 2014 Nov; 124(23):3398-408. PubMed ID: 25253771
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibitor development in previously untreated patients with hemophilia A: a prospective long-term follow-up comparing plasma-derived and recombinant products.
    Kreuz W; Ettingshausen CE; Zyschka A; Oldenburg J; Saguer IM; Ehrenforth S; Klingebiel T
    Semin Thromb Hemost; 2002 Jun; 28(3):285-90. PubMed ID: 12098090
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lack of evidence for increased inhibitor incidence in patients switched from plasma-derived to recombinant factor VIII.
    Scharrer I; Ehrlich HJ
    Haemophilia; 2001 Jul; 7(4):346-8. PubMed ID: 11442637
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Low risk of inhibitor formation in haemophilia A patients following en masse switch in treatment to a third generation full length plasma and albumin-free recombinant factor VIII product (ADVATE®).
    Bacon CL; Singleton E; Brady B; White B; Nolan B; Gilmore RM; Ryan C; Keohane C; Jenkins PV; O'Donnell JS
    Haemophilia; 2011 May; 17(3):407-11. PubMed ID: 21382134
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Frequency of inhibitor development in severe haemophilia A children treated with cryoprecipitate and low-dose immune tolerance induction.
    ElAlfy MS; Tantawy AA; Ahmed MH; Abdin IA
    Haemophilia; 2000 Nov; 6(6):635-8. PubMed ID: 11122388
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recombinant factor concentrates may increase inhibitor development: a single centre cohort study.
    Strauss T; Lubetsky A; Ravid B; Bashari D; Luboshitz J; Lalezari S; Misgav M; Martinowitz U; Kenet G
    Haemophilia; 2011 Jul; 17(4):625-9. PubMed ID: 21299743
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibitor incidence in haemophilia A under exclusive use of a third-generation recombinant factor VIII concentrate: results of the HEMFIL Cohort Study.
    Jardim LL; van der Bom J; Brommonschenkel CC; Gouw SC; Rezende SM;
    Br J Haematol; 2019 Jul; 186(1):152-155. PubMed ID: 30556277
    [No Abstract]   [Full Text] [Related]  

  • 34. First prospective report on immune tolerance in poor risk haemophilia A inhibitor patients with a single factor VIII/von Willebrand factor concentrate in an observational immune tolerance induction study.
    Kreuz W; Escuriola Ettingshausen C; Vdovin V; Zozulya N; Plyushch O; Svirin P; Andreeva T; Bubanská E; Campos M; Benedik-Dolničar M; Jiménez-Yuste V; Kitanovski L; Klukowska A; Momot A; Osmulskaya N; Prieto M; Šalek SZ; Velasco F; Pavlova A; Oldenburg J; Knaub S; Jansen M; Belyanskaya L; Walter O; ;
    Haemophilia; 2016 Jan; 22(1):87-95. PubMed ID: 26202305
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Source and purity of factor VIII products as risk factors for inhibitor development in patients with hemophilia A.
    Mancuso ME; Mannucci PM; Rocino A; Garagiola I; Tagliaferri A; Santagostino E
    J Thromb Haemost; 2012 May; 10(5):781-90. PubMed ID: 22452823
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immune tolerance induction in haemophilia A patients with high-responding inhibitors to factor VIII: experience at a single institution.
    Rocino A; Papa ML; Salerno E; Capasso F; Miraglia E; de Biasi R
    Haemophilia; 2001 Jan; 7(1):33-8. PubMed ID: 11136378
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hemophilia treatment. Factor VIII inhibitors with recombinant products: prospective clinical trials.
    Lusher JM
    Haematologica; 2000 Oct; 85(10 Suppl):2-5; discussion 5-6. PubMed ID: 11187864
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Frequency of inhibitor development in haemophiliacs treated with low-purity factor VIII.
    Addiego J; Kasper C; Abildgaard C; Hilgartner M; Lusher J; Glader B; Aledort L
    Lancet; 1993 Aug; 342(8869):462-4. PubMed ID: 8102429
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibitors in young boys with haemophilia.
    Lusher JM
    Baillieres Best Pract Res Clin Haematol; 2000 Sep; 13(3):457-68. PubMed ID: 11030045
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Epidemiology of inhibitor formation with recombinant factor VIII replacement therapy.
    Peerlinck K; Hermans C
    Haemophilia; 2006 Nov; 12(6):579-90. PubMed ID: 17083507
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.